Another regulator, Kristine Blackwood, joins the ranks of the lobbyists.
Do your tour and then cash in. The Washington way baby!
As a Democrat she’ll be particularly well positioned. The former senator will be able to occupy the enviro/oil industry sweet spot quite comfortably. Lots of money (one way or another) on both sides of that political equation.
The great thing about being a Senator is that if one does happen to lose, one is pretty much guaranteed a significant bump up in pay if one chooses to wander the green pastures of K Street, Lobbyland, Gucci Gulch, after one’s congressional career. If one can’t have direct power, piles of cash can soothe the lust.
No big deal. So what if the former Republican head of the Senate Trent Lott and his Democrat buddy John Breaux now work for the bank which funnels much of the money from the Russian petroleum industry? I mean what could possibly be wrong with that? It’s not like Putin is rolling his army into the Ukraine or anything and threatening to cut off natural gas pipelines to Europe before winter begins. No, no, it’s totally cool.
Eric Cantor up and quit on Thursday. It seems that life outside of House leadership was just too much for him to bear. Even for 4 months. Way to serve your district Mr. Cantor. Way to do the honorable thing.
The small government people keep harshing the lobbyist’s buzz, man.
And the Redskins have decided to change their name to the Washington Fighting Boehners. Of course the franchise will continue to lose.
The pharmaceutical lobby is the most influential in Washington DC according to a recent survey by APCO Worldwide.
Another good one from the Examiner.
Who writes the laws? The lobbyists.This isn’t completely true, but it is true to a very large extent as this article explains.
The thicker the law, the more opaque the legislation, the more opportunities there are to make money. There’s a reason Obamacare is a stack of papers taller than a man, same for Dodd-Frank. Both laws deal with impossibly complex areas of the economy best left to market mechanisms. To a very large extent the problems which both Obamacare and Dodd-Frank seek to address,